A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
NA
This is a single-center, prospective, randomized, open-label clinical trial...
Status
Not Yet Recruiting
Location
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
PHASE3
The study evaluated the efficacy and safety of letermovir (MK-8228) for the...
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
PHASE1
This phase Ib trial tests the safety, side effects, and how well cytomegalo...
A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
PHASE3
The purpose of this study is to evaluate the efficacy and safety of a once-...